Amyloidosis

2008 BMT Tandem Meetings (February 13-17, San Diego)

Angela Dispenzieri, Giampaolo Merlini, Raymond L. Comenzo

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

AL amyloidosis is a rare disease in which immunoglobulin light chains are deposited as aggregated interstitial fibrils that can compromise organ function and lead to death. The risks that patients with amyloidosis face include late diagnosis, misdiagnosis of amyloid type, untimely and ineffective therapy, and toxicities of therapy. The goals of treatment are (1) reduction or elimination of the amyloid-forming protein, usually a free immunoglobulin light chain measured by the serum-free light chain assay; (2) support of the patient pending hematologic response and improvement; and (3) stabilization of organ function. Whenever possible, patients should be treated on clinical trials.

Original languageEnglish (US)
Pages (from-to)6-11
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume14
Issue number1 SUPPL.
DOIs
StatePublished - Jan 2008

Fingerprint

Amyloidosis
Immunoglobulin Light Chains
Amyloidogenic Proteins
Delayed Diagnosis
Rare Diseases
Diagnostic Errors
Amyloid
Therapeutics
Clinical Trials
Light
Serum

ASJC Scopus subject areas

  • Transplantation

Cite this

Amyloidosis : 2008 BMT Tandem Meetings (February 13-17, San Diego). / Dispenzieri, Angela; Merlini, Giampaolo; Comenzo, Raymond L.

In: Biology of Blood and Marrow Transplantation, Vol. 14, No. 1 SUPPL., 01.2008, p. 6-11.

Research output: Contribution to journalArticle

Dispenzieri, Angela ; Merlini, Giampaolo ; Comenzo, Raymond L. / Amyloidosis : 2008 BMT Tandem Meetings (February 13-17, San Diego). In: Biology of Blood and Marrow Transplantation. 2008 ; Vol. 14, No. 1 SUPPL. pp. 6-11.
@article{a5eb5e88741a40a08c8aa655115e8828,
title = "Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego)",
abstract = "AL amyloidosis is a rare disease in which immunoglobulin light chains are deposited as aggregated interstitial fibrils that can compromise organ function and lead to death. The risks that patients with amyloidosis face include late diagnosis, misdiagnosis of amyloid type, untimely and ineffective therapy, and toxicities of therapy. The goals of treatment are (1) reduction or elimination of the amyloid-forming protein, usually a free immunoglobulin light chain measured by the serum-free light chain assay; (2) support of the patient pending hematologic response and improvement; and (3) stabilization of organ function. Whenever possible, patients should be treated on clinical trials.",
author = "Angela Dispenzieri and Giampaolo Merlini and Comenzo, {Raymond L.}",
year = "2008",
month = "1",
doi = "10.1016/j.bbmt.2007.10.026",
language = "English (US)",
volume = "14",
pages = "6--11",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "1 SUPPL.",

}

TY - JOUR

T1 - Amyloidosis

T2 - 2008 BMT Tandem Meetings (February 13-17, San Diego)

AU - Dispenzieri, Angela

AU - Merlini, Giampaolo

AU - Comenzo, Raymond L.

PY - 2008/1

Y1 - 2008/1

N2 - AL amyloidosis is a rare disease in which immunoglobulin light chains are deposited as aggregated interstitial fibrils that can compromise organ function and lead to death. The risks that patients with amyloidosis face include late diagnosis, misdiagnosis of amyloid type, untimely and ineffective therapy, and toxicities of therapy. The goals of treatment are (1) reduction or elimination of the amyloid-forming protein, usually a free immunoglobulin light chain measured by the serum-free light chain assay; (2) support of the patient pending hematologic response and improvement; and (3) stabilization of organ function. Whenever possible, patients should be treated on clinical trials.

AB - AL amyloidosis is a rare disease in which immunoglobulin light chains are deposited as aggregated interstitial fibrils that can compromise organ function and lead to death. The risks that patients with amyloidosis face include late diagnosis, misdiagnosis of amyloid type, untimely and ineffective therapy, and toxicities of therapy. The goals of treatment are (1) reduction or elimination of the amyloid-forming protein, usually a free immunoglobulin light chain measured by the serum-free light chain assay; (2) support of the patient pending hematologic response and improvement; and (3) stabilization of organ function. Whenever possible, patients should be treated on clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=37349005881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349005881&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2007.10.026

DO - 10.1016/j.bbmt.2007.10.026

M3 - Article

VL - 14

SP - 6

EP - 11

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 1 SUPPL.

ER -